Literature DB >> 8252036

Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease.

R Kaul1, G P Gao, K Balamurugan, R Matalon.   

Abstract

Canavan disease, an autosomal recessive leukodystrophy, is caused by deficiency of aspartoacylase and accumulation of N-acetylaspartic acid in brain. We have cloned the human aspartoacylase (ASP) cDNA spanning 1,435 basepairs, and show that the isolated cDNA expresses aspartoacylase activity in bacteria. Furthermore, an A to C base change, at nucleotide 854, has been found in 85% of the 34 Canavan alleles tested so far. This base change results in a missense Glu285Ala mutation that is predicted to be part of the catalytic domain of aspartoacylase. The data suggest that the catalytic centre of aspartoacylase involves a triad of Ser, His and Glu residues. Our findings have implications for diagnosis and screening of Canavan disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8252036     DOI: 10.1038/ng1093-118

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  62 in total

1.  The key is in the genes, or is it...? With the human genome project completed, the question is 'what comes next'?

Authors:  A Moore
Journal:  EMBO Rep       Date:  2000-08       Impact factor: 8.807

Review 2.  Biochemistry and molecular biology of Canavan disease.

Authors:  R Matalon; K Michals-Matalon
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

3.  Nuclear-cytoplasmic localization of acetyl coenzyme a synthetase-1 in the rat brain.

Authors:  Prasanth S Ariyannur; John R Moffett; Chikkathur N Madhavarao; Peethambaran Arun; Nisha Vishnu; David M Jacobowitz; William C Hallows; John M Denu; Aryan M A Namboodiri
Journal:  J Comp Neurol       Date:  2010-08-01       Impact factor: 3.215

4.  Tremor-ataxia with central hypomyelination (TACH) leukodystrophy maps to chromosome 10q22.3-10q23.31.

Authors:  Geneviève Bernard; Isabelle Thiffault; Martine Tetreault; Maria Lisa Putorti; Isabelle Bouchard; Michel Sylvain; Serge Melançon; Rachel Laframboise; Pierre Langevin; Jean-Pierre Bouchard; Michel Vanasse; Adeline Vanderver; Guillaume Sébire; Bernard Brais
Journal:  Neurogenetics       Date:  2010-07-17       Impact factor: 2.660

5.  Expression and localization of myosin-1d in the developing nervous system.

Authors:  Andrew E Benesh; Jonathan T Fleming; Chin Chiang; Bruce D Carter; Matthew J Tyska
Journal:  Brain Res       Date:  2012-01-08       Impact factor: 3.252

6.  Dietary triheptanoin rescues oligodendrocyte loss, dysmyelination and motor function in the nur7 mouse model of Canavan disease.

Authors:  Jeremy S Francis; Vladimir Markov; Paola Leone
Journal:  J Inherit Metab Dis       Date:  2013-11-28       Impact factor: 4.982

7.  Transcriptional regulation of N-acetylaspartate metabolism in the 5xFAD model of Alzheimer's disease: evidence for neuron-glia communication during energetic crisis.

Authors:  Samantha Zaroff; Paola Leone; Vladimir Markov; Jeremy S Francis
Journal:  Mol Cell Neurosci       Date:  2015-03-10       Impact factor: 4.314

8.  The frequency of the C854 mutation in the aspartoacylase gene in Ashkenazi Jews in Israel.

Authors:  O N Elpeleg; Y Anikster; V Barash; D Branski; A Shaag
Journal:  Am J Hum Genet       Date:  1994-08       Impact factor: 11.025

9.  Prenatal detection of Canavan disease (aspartoacylase deficiency) by DNA analysis.

Authors:  O N Elpeleg; A Shaag; Y Anikster; C Jakobs
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

10.  Long-term follow-up after gene therapy for canavan disease.

Authors:  Paola Leone; David Shera; Scott W J McPhee; Jeremy S Francis; Edwin H Kolodny; Larissa T Bilaniuk; Dah-Jyuu Wang; Mitra Assadi; Olga Goldfarb; H Warren Goldman; Andrew Freese; Deborah Young; Matthew J During; R Jude Samulski; Christopher G Janson
Journal:  Sci Transl Med       Date:  2012-12-19       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.